Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Immuron Double Digit 3Q Sales Growth
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
Immuron Reports HY26 Results and Strategic Reset
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.